Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system

27 Aug 2020

Abstract excerpt

Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are considered a breakthrough in cancer therapy. Currently approved for breast cancer treatment, CDK4/6 inhibitors are extensively tested in other cancer subtypes. Frequently observed side effects include hematological abnormalities such as reduced numbers of neutrophils, erythroid cells and platelets that are associated with anemia, bleeding and a higher risk...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Chronic Lymphocytic Leukemia Research
Share to Lung Cancer Research Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32855282
DOI: 10.3324/haematol.2020.256313

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic systemPMID 32855282Read ↗

CDK6 as a key regulator of hematopoietic and leukemic stem cell activationSemantic proximity Read ↗

Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis.Semantic proximity Read ↗

CDK4 and CDK6 kinases: From basic science to cancer therapySemantic proximity Read ↗

Hematopoiesis specific loss of Cdk2 and Cdk4 results in increased erythrocyte size and delayed platelet recovery following stress.Semantic proximity Read ↗

Targeting cell cycle regulators in hematologic malignanciesSemantic proximity Read ↗

CDK6 kinase activity is required for thymocyte development.Semantic proximity Read ↗

Targeting CDK6 in cancer: State of the art and new insightsSemantic proximity Read ↗

Cell cycle and cancer: genetic analysis of the role of cyclin-dependent kinases.Semantic proximity Read ↗

A Requirement for Cyclin-Dependent Kinase 6 in Thymocyte Development and TumorigenesisSemantic proximity Read ↗

Targeting Cyclins and Cyclin-Dependent Kinases in Cancer: Lessons from Mice, Hopes for Therapeutic Applications in HumansSemantic proximity Read ↗

Cell-specific responses to loss of cyclin-dependent kinases.Semantic proximity Read ↗

Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies—Current Understanding, (Pre-)Clinical Application and Promising ApproachesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.